Sphingosylphosphorylcholine

Sphingosylphosphorylcholine 是一种生物活性脂质,是血浆高密度脂蛋白的主要成分,与 OGR1 结合(Kd 为 33.3 nM),可触发延迟的 Smad2 磷酸化、上调 α-SMA 表达、激活 TRPM3、减少凋亡 (Apoptosis)、上调 uPA 及其受体 uPA-R 的表达,发挥抗凋亡、抗心肌肥厚及促伤口愈合作用,可在小鼠中引发搔抓行为,并可用于特应性皮炎、早幼粒细胞白血病、心力衰竭、心肌缺血/再灌注损伤、卵巢癌、乳腺癌、胰腺癌以及遗传性愈合障碍糖尿病的皮肤伤口愈合障碍相关研究。
产品编号: MS-X59243 纯度: 99.50% CAS No.: 1670-26-4 分子式: C23H49N2O5P 分子量: 464.62
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Sphingosylphosphorylcholine 是一种生物活性脂质,是血浆高密度脂蛋白的主要成分,与 OGR1 结合(Kd 为 33.3 nM),可触发延迟的 Smad2 磷酸化、上调 α-SMA 表达、激活 TRPM3、减少凋亡 (Apoptosis)、上调 uPA 及其受体 uPA-R 的表达,发挥抗凋亡、抗心肌肥厚及促伤口愈合作用,可在小鼠中引发搔抓行为,并可用于特应性皮炎、早幼粒细胞白血病、心力衰竭、心肌缺血/再灌注损伤、卵巢癌、乳腺癌、胰腺癌以及遗传性愈合障碍糖尿病的皮肤伤口愈合障碍相关研究。

生物实验数据

生物活性 Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a Kd of 33.3 nM, triggers delayed Smad2 phosphorylation, upregulates α-SMA expression, activates TRPM3, reduces apoptosis (Apoptosis), upregulates the expression of uPA and its receptor uPA-R, exerts anti-apoptotic, anti-cardiac hypertrophic, and wound-healing-promoting effects, induces scratching behavior in mice, and can be used in research related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and impaired skin wound healing in hereditary healing disorder diabetes.
IC50 & Target

TRPM3

 

体外研究
(In Vitro)

Sphingosylphosphorylcholine (10 nM-50 μM) 以剂量依赖的方式激活 TRPM3,从而诱导 HEK293T 细胞外钙离子内流并动员细胞内钙库。
Sphingosylphosphorylcholine (15-20 μM; 15 min-4 h) 可以浓度和时间依赖的方式,在小鼠胚胎干细胞来源的类胚体向外生长物中强效诱导肌动蛋白应力纤维形成和黏着斑组装。
Sphingosylphosphorylcholine (10 μM) 可抑制血管紧张素 II 诱导的新生小鼠心肌细胞肥大。
Sphingosylphosphorylcholine (10 μM) 可保护新生大鼠心肌细胞免受 210 min 缺氧后再经 150 min 复氧诱导的细胞凋亡。
Sphingosylphosphorylcholine 可高亲和力 (Kd = 33.3 nM)、高特异性地与转染 OGR1 的 HEK293 细胞中的 OGR1 结合。
Sphingosylphosphorylcholine (0.1-5 μM; 24 h) 可在 24 h 内以剂量依赖方式上调正常包皮角质形成细胞表面尿激酶型纤溶酶原激活物 (uPA) 及其受体 uPA-R 的表达。

Cell Proliferation Assay

Cell Line: human NB4 promyelocytic leukemia cells
Concentration: 12.5-15 μM
Incubation Time: 48-96 h
Result: Caused a 45% decrease in NB4 cell numbers after 96 h compared to untreated controls.
Significantly increased relative CD11c mRNA expression at 48 h and 96 h, reaching ~10% of the effect of all-trans retinoic acid (ATRA).
Significantly increased relative CD18 mRNA expression at 48 h and 96 h, reaching 8-18% of the effect of ATRA.
Substantially increased cell surface CD11c protein expression, reaching ~20% of the effect of ATRA.
体内研究
(In Vivo)

Sphingosylphosphorylcholine (每部位 100 nmol;皮内注射) 可在 Mus musculus 中诱导显著的搔抓行为,但不会引发疼痛相关的擦拭行为,证实了其致痒活性。
Sphingosylphosphorylcholine (10 μM/kg/天;皮下注射;每日;持续 4 周) 可将小鼠的存活率提升至 63%,并通过抑制 CaM-JNK/p38 信号通路缓解压力超负荷诱导的心肌肥厚、纤维化与细胞凋亡。
Sphingosylphosphorylcholine (0.625-2.5 μg/g body weight;静脉注射;冠状动脉结扎前 30 分钟预防性处理,或再灌注开始时处理) 可通过依赖 S1P3 受体的机制呈剂量依赖性缩小心肌梗死面积:预防性处理时缩小幅度可达 50%,再灌注时处理缩小幅度为 40%。
Sphingosylphosphorylcholine (2 μM;局部) 可在基因层面愈合能力受损的糖尿病 db/db 小鼠中统计学显著地促进皮肤伤口愈合,表现为伤口面积减小、肉芽组织体积增大以及未再上皮化创面长度缩短。

Animal Model: C57BL/6 (male, 10- to 14-week-old)
Dosage: 100 nmol/site
Administration: i.d.; single administration
Result: Induced a mean of 74.83 ± 27.46 scratching bouts per 30 min, compared to 12 ± 4.374 scratching bouts in vehicle-treated mice.
Did not induce a significant change in wiping behavior, with a mean of 4.000 ± 0.578 wiping bouts per 30 min, compared to 6.333 ± 0.989 in vehicle-treated mice.\nInduced a mean of 89.67 ± 7.756 scratching bouts per 30 min, compared to 14.33 ± 3.303 scratching bouts in vehicle-treated mice.
Animal Model: C57BL/6 (male, 6-8 weeks old; pressure overload induced via trans-aortic constriction surgery)
Dosage: 10 μM/kg/day
Administration: s.c.; daily; 4 weeks
Result: Increased survival rate to 63% in TAC mice.
Significantly increased left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) relative to untreated TAC mice.
Significantly reduced the ratios of heart weight to body weight (HW/BW) and left ventricular weight to body weight (LW/BW) relative to untreated TAC mice.
Reduced cardiomyocyte cross-sectional area relative to untreated TAC mice.
Decreased the mRNA and protein expression of hypertrophy markers ANP, BNP, and β-MHC compared to untreated TAC mice.
Reduced left ventricular collagen volume fraction relative to untreated TAC mice.
Decreased protein and mRNA expression of fibrosis markers collagen I, collagen III, α-SMA, TGF-β, and fibronectin relative to untreated TAC mice.
Reduced the number of TUNEL-positive apoptotic cardiomyocytes relative to untreated TAC mice.
Decreased protein expression of Bax in TAC mouse hearts compared to untreated TAC mice.
Increased protein expression of Bcl-2 in TAC mouse hearts compared to untreated TAC mice.
Reduced the levels of CaM, phosphorylated JNK (p-JNK), and phosphorylated p38 (p-p38) in TAC mouse hearts compared to untreated TAC mice.
Animal Model: Outbred Swiss mice (strain-matched, age-matched, sex-matched); C57BL/6 wild-type mice; S1P3-deficient (S1P3-/-) mice on C57BL/6 background (strain-matched, age-matched, sex-matched)
Dosage: 0.625 μg/g body weight; 1.25 μg/g body weight; 2.5 μg/g body weight
Administration: i.v.; 30 minutes before coronary ligation; single dose; i.v. (therapeutically at reperfusion onset; single dose)
Result: Reduced infarct size by 23% (0.625 μg/g preventive).
Reduced infarct size by 36% (1.25 μg/g preventive).
Reduced infarct size by 50% (2.5 μg/g preventive).
Reduced infarct size by 40% (1.25 μg/g at reperfusion).
Reduced polymorphonuclear neutrophil recruitment to infarcted area from 629 ± 45 PMN/mm2 to 332 ± 43 PMN/mm2 (preventive treatment).
Reduced TUNEL-positive apoptotic cells in area at risk from 920 ± 225 cells/mm2 to 643 ± 66 cells/mm2 (preventive treatment).
Reduced infarction/area at risk to 29 ± 3.8% vs control 34 ± 2% (1.25 μg/g preventive in C57BL/6 wild-type mice).
Showed no effect on infarct size (105 ± 9% of vehicle control, no significant difference) in S1P3-/- mice.
性状 固体
颜色 White to off-white

化学信息

分子量 464.62
分子式 C23H49N2O5P
CAS No. 1670-26-4

储存&溶解度

储存方式

-20°C, protect from light, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

Ethanol 中的溶解度 : 2.5 mg/mL (5.38 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol1 mM2.1523 mL10.7615 mL21.5230 mL53.8074 mL
5 mM0.4305 mL2.1523 mL4.3046 mL10.7615 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础